Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Jul 12, 2018 9:15am
166 Views
Post# 28304953

RE:RE:RE:RE:Interesting trading day

RE:RE:RE:RE:Interesting trading day

I agree, share price is baffling, not sure we shoudl be at $1 yet, but at least in the 0.60-0.70 range.
Basically I believe we are undervalued by half price now and will double again after top line results. 
Would sure be nice to have them post a NR saying they are starting the study this month with top line results expected in January. I think that gets us over 0.50 (still worth more in my opinion).

I think this is a 12-48 month hold. 
At 12 months in we should hopefully have a partnership deal taking us well north of $2 a share and we continue to climb up until our first year of sales which gets us near $1 Billion in sales plus other pipeline drugs raises our vlaue to $8-$12 in 48 months.

Think about that, $1000 today buys you 2500 shares and in 4 years is worth $30,000.
Or like others, 100,000 shares bought in at 0.10 a year ago for $10,000 invested will get you $1.2 Million. 
Now that's somethign to be optimistic about. I can wait 4 years for that (especially if you multiply that initial investment).

 

Bullboard Posts